Long-term open-label cardiac imaging study of acoramidis in ATTR-CM

Phase 4, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and transthyretin amyloidosis (ATTR), sponsored by Eidos Therapeutics. Primary endpoints: Response based on improved LVEF or LVSVi at Month 36 and Incidence of treatment-emergent adverse events and serious adverse events. Planned start Sep 2026; status: authorised.